

Paradigm Biopharmaceuticals Ltd

11:54 13 Feb 2020

Paradigm Biopharmaceuticals presents patient-centric research at World MPS Symposium

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has presented its poster presentation for MPS VI, a rare autosomal lysosomal storage disorder, at the World MPS Symposium in Orlando, Florida.

The company presented outcomes from a patient focus group which aimed to identify and validate clinical endpoints thus producing the most clinically relevant endpoints for MPS subjects.

Paradigm chief medical officer Dr Donna Skerrett said: "Improving the lives of MPS patients requires a deep understanding of their medical condition, experiences, needs and priorities of both patient and caregiver.

"The patient-centric research conducted by the Paradigm team provides an opportunity to adopt and use these as a reference point for consistent patient engagement and to develop clinically meaningful endpoints, which is especially important in orphan indications".

Current treatment includes enzyme replacement therapy (ERT) which acts to reduce non-neurological symptoms and pain, however, many patients continue to report ongoing issues.

Paradigm is focused on repurposing the injectable drug pentosan polysulphate sodium (iPPS) to treat inflammation.

Clarifying patient needs

The objective of the company's research was to engage patients with MPS VI, and their caregivers in the drug development process, to better understand the range of symptoms and the impact on function and activities of daily living.

A focus group was established with nine patients age 4-18 and their caregivers with a series of open-ended and polling questions to gain comprehensive understanding into the specific needs of patients suffering from the orphan disease.

MPS patients found the following activities most challenging:

- 33.3% of patients/caregivers cited mobility and independence as their most challenging;
- Fine motor tasks were reported by 78% as the most or second most challenging; and
- 33.3% of patients/caregivers cited sleep as most or second most challenging.

Patient-centric development


Paradigm chief executive officer Paul Rennie said: "The research into the clinical unmet needs of MPS patients conducted by the Paradigm team and the presentation of the poster at the World MPS Symposium provides the company an important understanding of clinically meaningful end-points that will be incorporated into our clinical trial development program for iPPS in this orphan indication.

"This is an important step for Paradigm as we continue to work with key opinion leaders and MPS experts about how to

Price: 3.07

Market Cap: \$689.94 m

1 Year Share Price Graph



June 2019 November 2019 June 2020

Share Information

Code: PAR

Listing: ASX

52 week High Low
4.5 1.08

Sector: Pharma & Biotech

Website: www.paradigmbiopharma.com

Company Synopsis:

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com.au

achieve the best outcomes for patients.

"By having a trial design that patients see benefit from allows for better recruitment, retention and higher reimbursement potential should the trial be successful".

The company believes this approach will not only assist in the recruitment and retention of patients for the trial but will likely improve market penetration of iPPS for treatment of MPS patients in conjunction with ERT - as the company moves toward commercialisation.

Scientific advice submission

The endpoints identified in the research will be discussed as part of the joint Scientific Advice Submission to the food and drug administration (FDA) USA and the European medicines agency (EMA) regulatory bodies.

The FDA and EMA have agreed to a joint parallel scientific advice submission, with the procedure to commence in March.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +61 (0)2 9280 0700 action@proactiveinvestors.com.au

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount of up to Twenty Five Thousand dollars (\$25,000).